The approval was based on the Phase III SERENA-6 trial that used ctDNA testing to detect ESR1 resistance mutations and inform treatment switching.
A Children's Hospital of Philadelphia team said their case study highlighted the need for increased safety monitoring.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results